Celltrion has developed first-of-its-kind ZYMFENTRA™ (infliximab-dyyb), a pioneering subcutaneous (SC) formulation of infliximab.
ZYMFENTRA is a prescription medication administered via injection beneath the skin. It works by inhibiting the activity of tumour necrosis factor-alpha (TNF-alpha), a protein that can be excessively produced in response to certain diseases, leading to the immune system attacking healthy tissues.
This medication is approved for adults with moderately to severely active ulcerative colitis (UC) or moderately to severely active Crohn's disease (CD) following initial treatment with an intravenously administered infliximab product.
Infliximab has long been recognised as an effective therapy for individuals with ulcerative colitis or Crohn's disease. The introduction of a subcutaneous administration method represents a significant advancement in patient care, providing a more convenient treatment option for those in the U.S. This enables patients to better manage their condition with greater flexibility.
Patients living with ulcerative colitis and Crohn's disease are not only seeking safe and effective treatments for incremental improvement but also convenient options for managing these chronic conditions.
The availability of ZYMFENTRA will offer patients enhanced control over their treatment, with added flexibility and convenience.
